Tags:Bemarituzumab 代理商,Bemarituzumab 价格,Bemarituzumab 供应商, Bemarituzumab supplier,Bemarituzumab purchase,Bemarituzumab 购买,Bemarituzumab 销售
Description
Bemarituzumab (bema), a first-in-class humanized IgG1 monoclonal antibody, selectively binds to 2b Isoform of thefibroblast growth factor receptor (FGFR2b). Bemarituzumab (FPA144) is a first-in-class humanized immunoglobulin G1 monoclonal antibody specific to the splice-variant FGFR2b that inhibits binding of the ligands FGF7, FGF10, and FGF22. Specifically, bemarituzumab does not inhibit binding of FGF23, the ligand responsible for phosphate and vitamin D metabolism, thereby potentially avoiding the risk of hyperphosphatemia associated with pan-FGFR tyrosine kinase inhibitors. Bemarituzumab is also glycoengineered for increased affinity for the human Fc gamma RIIIA receptor expressed on natural killer cells, enabling enhanced antibody-dependent cellmediated cytotoxicity.
Catalog No.
DHD47901
Host species
Humanized
Species reactivity
Human
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Concentration
1 mg/ml
Purity
>95%
Clonality
Monoclonal
Isotype
IgG1-kappa
Applications
Research Grade Biosimilar
Target
K-sam, KSAM, CD332, Keratinocyte growth factor receptor, Fibroblast growth factor receptor 2, FGFR-2, FGFR2, KGFR, BEK
Purification
Protein A or G purified from cell culture supernatant.
Endotoxin level
Please contact with the lab for this information.
Expression system
XtenCHO
Accession
P21802
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.Store at +4°C short term (1-2 weeks).Store at -20 °C 12 months. Store at -80°C long term.
Alternative Names
FPA144 ,FPA-144, FPA114-A, CAS: 1952272-74-0
Note
For research use only. Not suitable for clinical or therapeutic use.
关键字: Bemarituzumab;贝马里妥珠单抗;1952272-74-0;K-sam, KSAM;FGFR2, KGFR;
普健生物依托自主研发的高通量活性蛋白表达系统,Single B细胞抗体发现技术平台,噬菌体展示抗体库技术和杂交瘤抗体开发平台,抗体表达、抗体人源化和稳定细胞株构建平台,与各研究机构展开技术服务项目合作,助力IVD检测、疫苗生产、重组抗体开发。
普健生物一站式抗体发现平台,专注于活性蛋白,功能性抗体开发。